このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Evolus 将来の成長

Future 基準チェック /66

Evolus利益と収益がそれぞれ年間66.4%と23.1%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に33.9% 66.4%なると予測されています。

主要情報

66.4%

収益成長率

66.4%

EPS成長率

Pharmaceuticals 収益成長	27.3%
収益成長率	23.1%
将来の株主資本利益率	33.9%
アナリストカバレッジ	Good
最終更新日	06 Jun 2024

今後の成長に関する最新情報

Analysts Are Updating Their Evolus, Inc. (NASDAQ:EOLS) Estimates After Its First-Quarter Results

May 10

The Evolus, Inc. (NASDAQ:EOLS) Full-Year Results Are Out And Analysts Have Published New Forecasts

Mar 10

Recent updates

Evolus: Chiseling Away At The Aesthetic Market

May 22

Analysts Are Updating Their Evolus, Inc. (NASDAQ:EOLS) Estimates After Its First-Quarter Results

May 10

Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028

Mar 20

The Evolus, Inc. (NASDAQ:EOLS) Full-Year Results Are Out And Analysts Have Published New Forecasts

Mar 10

Evolus, Inc. (NASDAQ:EOLS) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Jan 18

Evolus, Inc.'s (NASDAQ:EOLS) Shares Climb 27% But Its Business Is Yet to Catch Up

Jan 18

Would Evolus (NASDAQ:EOLS) Be Better Off With Less Debt?

Jun 16

Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Nov 06

Evolus concludes certain royalty payments related to settlement of IP rights dispute

Sep 21

業績と収益の成長予測

NasdaqGM:EOLS - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	456	47	98	126	7
12/31/2025	348	-13	17	27	7
12/31/2024	262	-45	-24	-18	7
3/31/2024	220	-60	-26	-24	N/A
12/31/2023	202	-62	-36	-34	N/A
9/30/2023	185	-63	-46	-44	N/A
6/30/2023	169	-66	-63	-60	N/A
3/31/2023	156	-72	-70	-67	N/A
12/31/2022	149	-74	-88	-85	N/A
9/30/2022	140	-79	-87	-85	N/A
6/30/2022	132	-79	-101	-100	N/A
3/31/2022	121	-71	-64	-63	N/A
12/31/2021	100	-47	-34	-33	N/A
9/30/2021	86	-139	-27	-27	N/A
6/30/2021	77	-131	-10	-8	N/A
3/31/2021	58	-137	-40	-38	N/A
12/31/2020	57	-163	-61	-58	N/A
9/30/2020	55	-67	-76	-72	N/A
6/30/2020	51	-82	-87	-83	N/A
3/31/2020	45	-99	-107	-102	N/A
12/31/2019	35	-90	-98	-93	N/A
9/30/2019	15	-88	-93	-89	N/A
6/30/2019	2	-73	-73	-70	N/A
3/31/2019	N/A	-52	-43	-43	N/A
12/31/2018	N/A	-47	-26	-26	N/A
9/30/2018	N/A	-30	-15	-15	N/A
6/30/2018	N/A	-21	-12	-12	N/A
3/31/2018	N/A	-7	-10	-10	N/A
12/31/2017	N/A	-4	N/A	-13	N/A
9/30/2017	N/A	-13	N/A	-14	N/A
6/30/2017	N/A	-14	N/A	-13	N/A
3/31/2017	N/A	-18	N/A	-14	N/A
12/31/2016	N/A	-20	N/A	-13	N/A

アナリストによる今後の成長予測

収入対貯蓄率: EOLSは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.4% ) よりも高い成長率であると考えられます。

収益対市場: EOLS今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: EOLS今後 3 年以内に収益を上げることが予想されます。

収益対市場: EOLSの収益 ( 23.1% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: EOLSの収益 ( 23.1% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: EOLSの自己資本利益率は、3年後には高くなると予測されています ( 33.9 %)

Evolus 将来の成長

Future 基準チェック /66

主要情報

今後の成長に関する最新情報

Analysts Are Updating Their Evolus, Inc. (NASDAQ:EOLS) Estimates After Its First-Quarter Results

Forecast breakeven date moved forward to 2025

Evolus, Inc. Reaffirms Financial Guidance for the Full Year 2024

The Evolus, Inc. (NASDAQ:EOLS) Full-Year Results Are Out And Analysts Have Published New Forecasts

Price target increased by 7.6% to US$22.29

Evolus, Inc. Reiterates Earnings Guidance for the Full Year 2024

Recent updates

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products

Evolus, Inc. Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting

Evolus: Chiseling Away At The Aesthetic Market

President recently sold US$204k worth of stock

Analysts Are Updating Their Evolus, Inc. (NASDAQ:EOLS) Estimates After Its First-Quarter Results

Forecast breakeven date moved forward to 2025

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Evolus, Inc. Reaffirms Financial Guidance for the Full Year 2024

Evolus, Inc. to Report Q1, 2024 Results on May 07, 2024

Evolus, Inc. Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra- Strength" 40U Formulation of Jeuveau

Evolus, Inc. Announces Board Changes

President recently sold US$1.3m worth of stock

Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028

Evolus, Inc. has completed a Follow-on Equity Offering in the amount of $50.00478 million.

The Evolus, Inc. (NASDAQ:EOLS) Full-Year Results Are Out And Analysts Have Published New Forecasts

Price target increased by 7.6% to US$22.29

Evolus, Inc. Reiterates Earnings Guidance for the Full Year 2024

Evolus, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Independent Director notifies of intention to sell stock

Evolus, Inc. (NASDAQ:EOLS) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Evolus, Inc.'s (NASDAQ:EOLS) Shares Climb 27% But Its Business Is Yet to Catch Up

Evolus, Inc. Announces Earnings Guidance for 2024

Evolus, Inc. Appoints Nareg Sagherian as Head of Global Investor Relations and Corporate Communications

New minor risk - Shareholder dilution

President recently sold US$822k worth of stock

President notifies of intention to sell stock

New minor risk - Insider selling

No longer forecast to breakeven

Evolus, Inc. Raises Earnings Guidance for the Full Year 2023

Price target increased by 12% to US$20.25

Evolus, Inc. Announces Results from the Phase 2 Clinical Study Evaluating the "Extra- strength" 40U Dose for Extended Duration of Jeuveau

Evolus, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Evolus, Inc. Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer

President recently sold US$152k worth of stock

Evolus, Inc. Unveils New Branding for Product Jeuveau to Reflect Growing and Evolving Consumers

New major risk - Negative shareholders equity

Second quarter 2023 earnings: EPS misses analyst expectations

New minor risk - Share price stability

Evolus, Inc. Revises Revenue Guidance for the Year 2023

Evolus Launches Nuceiva (Botulinum Toxin Type A) in Italy

Evolus Announces Successful Completion of Phase 2 Study Evaluating "Extra-Strength" Dose of Jeuveau (R)

Would Evolus (NASDAQ:EOLS) Be Better Off With Less Debt?

Price target increased by 9.4% to US$18.11

Consensus EPS estimates fall by 46%

Price target increased by 8.4% to US$17.22

Evolus, Inc. Provides Revenue Guidance for the Year 2023

Evolus, Inc. to Report Q1, 2023 Results on May 09, 2023

Full year 2022 earnings: EPS misses analyst expectations

Evolus, Inc. Announces "Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase Ii Data Results, Representing Prolonged 6-Month Performance

Evolus, Inc. Receives Regulatory Approval for Nuceiva® in Australia

Evolus, Inc. Provides Earnings Guidance for the Year 2023

Forecast to breakeven in 2025

Insufficient new directors

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Evolus, Inc. Provides Earnings Guidance for the Full Year 2022

Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Evolus, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Evolus concludes certain royalty payments related to settlement of IP rights dispute

Evolus: Turning That Frown Upside Down

Independent Director recently bought US$91k worth of stock

Evolus, Inc. Names Sandra Beaver as Its Chief Financial Officer, Effective September 5, 2022

Evolus appoints Experian's exec as CFO

Consensus forecasts updated

Forecast to breakeven in 2024

Is Evolus (NASDAQ:EOLS) Using Too Much Debt?

Second quarter 2022 earnings: Revenues exceed analyst expectations

Evolus, Inc. Reaffirms Revenue Guidance for Full Year 2022

Insufficient new directors

Evolus Q2 2022 Earnings Preview